These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35574502)

  • 1. Covaxin: An overview of its immunogenicity and safety trials in India.
    Sharma R; Tiwari S; Dixit A
    Bioinformation; 2021; 17(10):840-845. PubMed ID: 35574502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
    Ella R; Reddy S; Jogdand H; Sarangi V; Ganneru B; Prasad S; Das D; Raju D; Praturi U; Sapkal G; Yadav P; Reddy P; Verma S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Bhate A; Rai S; Panda S; Abraham P; Gupta N; Ella K; Bhargava B; Vadrevu KM
    Lancet Infect Dis; 2021 Jul; 21(7):950-961. PubMed ID: 33705727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
    Ella R; Vadrevu KM; Jogdand H; Prasad S; Reddy S; Sarangi V; Ganneru B; Sapkal G; Yadav P; Abraham P; Panda S; Gupta N; Reddy P; Verma S; Kumar Rai S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Rao V; Guleria R; Ella K; Bhargava B
    Lancet Infect Dis; 2021 May; 21(5):637-646. PubMed ID: 33485468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated vaccine Covaxin/BBV152: A systematic review.
    Ahmed TI; Rishi S; Irshad S; Aggarwal J; Happa K; Mansoor S
    Front Immunol; 2022; 13():863162. PubMed ID: 36016940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152).
    Sunagar R; Prasad SD; Ella R; Vadrevu KM
    Front Immunol; 2022; 13():1063679. PubMed ID: 36569867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.
    Vadrevu KM; Reddy S; Jogdand H; Ganneru B; Mirza N; Tripathy VN; Singh C; Khalatkar V; Prasanth S; Rai S; Ella R; Blackwelder W; Prasad S; Ella K
    Lancet Infect Dis; 2022 Sep; 22(9):1303-1312. PubMed ID: 35717995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects.
    Dotiwala F; Upadhyay AK
    Front Immunol; 2022; 13():940715. PubMed ID: 36177016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys.
    Singh P; Ujjainiya R; Prakash S; Naushin S; Sardana V; Bhatheja N; Singh AP; Barman J; Kumar K; Gayali S; Khan R; Rawat BS; Tallapaka KB; Anumalla M; Lahiri A; Kar S; Bhosale V; Srivastava M; Mugale MN; Pandey CP; Khan S; Katiyar S; Raj D; Ishteyaque S; Khanka S; Rani A; Promila ; Sharma J; Seth A; Dutta M; Saurabh N; Veerapandian M; Venkatachalam G; Bansal D; Gupta D; Halami PM; Peddha MS; Veeranna RP; Pal A; Singh RK; Anandasadagopan SK; Karuppanan P; Rahman SN; Selvakumar G; Venkatesan S; Karmakar MK; Sardana HK; Kothari A; Parihar DS; Thakur A; Saiļ¬ A; Gupta N; Singh Y; Reddu R; Gautam R; Mishra A; Mishra A; Gogeri I; Rayasam G; Padwad Y; Patial V; Hallan V; Singh D; Tirpude N; Chakrabarti P; Maity SK; Ganguly D; Sistla R; Balthu NK; A KK; Ranjith S; Kumar BV; Jamwal PS; Wali A; Ahmed S; Chouhan R; Gandhi SG; Sharma N; Rai G; Irshad F; Jamwal VL; Paddar MA; Khan SU; Malik F; Ghosh D; Thakkar G; Barik SK; Tripathi P; Satija YK; Mohanty S; Khan MT; Subudhi U; Sen P; Kumar R; Bhardwaj A; Gupta P; Sharma D; Tuli A; Ray Chaudhuri S; Krishnamurthi S; Prakash L; Rao CV; Singh BN; Chaurasiya A; Chaurasiyar M; Bhadange M; Likhitkar B; Mohite S; Patil Y; Kulkarni M; Joshi R; Pandya V; Mahajan S; Patil A; Samson R; Vare T; Dharne M; Giri A; Mahajan S; Paranjape S; Sastry GN; Kalita J; Phukan T; Manna P; Romi W; Bharali P; Ozah D; Sahu RK; Dutta P; Singh MG; Gogoi G; Tapadar YB; Babu EV; Sukumaran RK; Nair AR; Puthiyamadam A; Valappil PK; Pillai Prasannakumari AV; Chodankar K; Damare S; Agrawal VV; Chaudhary K; Agrawal A; Sengupta S; Dash D
    Comput Biol Med; 2022 Jul; 146():105419. PubMed ID: 35483225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host immune responses in aged rhesus macaques against BBV152, an inactivated SARS-CoV-2 vaccine, and cross-neutralization with beta and delta variants.
    Patil DR; Shete AM; Yadav PD; Sapkal GN; Deshpande GR; Kaushal H; Mohandas S; Fulari S; Jain R; Kumar A; Abraham P
    Front Immunol; 2023; 14():1161571. PubMed ID: 37187744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern.
    Vikkurthi R; Ansari A; Pai AR; Jha SN; Sachan S; Pandit S; Nikam B; Kalia A; Jit BP; Parray HA; Singh S; Kshetrapal P; Wadhwa N; Shrivastava T; Coshic P; Kumar S; Sharma P; Sharma N; Taneja J; Pandey AK; Sharma A; Thiruvengadam R; Grifoni A; Weiskopf D; Sette A; Bhatnagar S; Gupta N
    Nat Microbiol; 2022 Jul; 7(7):974-985. PubMed ID: 35681012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
    Desai D; Khan AR; Soneja M; Mittal A; Naik S; Kodan P; Mandal A; Maher GT; Kumar R; Agarwal A; Gowda NR; H V; Kumar P; Pandey S; Pandey RM; Kumar A; Ray A; Jorwal P; Nischal N; Choudhary A; Brijwal M; Madan K; Lodha R; Sinha S; Dar L; Wig N; Guleria R
    Lancet Infect Dis; 2022 Mar; 22(3):349-356. PubMed ID: 34826383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India.
    Chaudhary A; Madhavan R; Babji S; Raju R; Syed C; Kumar A; Saravanan P; Sharon Nikitha O; Leander Xavier JV; David Chelladurai JS; Deborah AA; George A; Kang G; Rose W
    Vaccine; 2023 Jul; 41(33):4808-4822. PubMed ID: 37357073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation.
    Ganneru B; Jogdand H; Daram VK; Das D; Molugu NR; Prasad SD; Kannappa SV; Ella KM; Ravikrishnan R; Awasthi A; Jose J; Rao P; Kumar D; Ella R; Abraham P; Yadav PD; Sapkal GN; Shete-Aich A; Desphande G; Mohandas S; Basu A; Gupta N; Vadrevu KM
    iScience; 2021 Apr; 24(4):102298. PubMed ID: 33723528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern.
    Kumar NP; Banurekha VV; Kumar CPG; Nancy A; Padmapriyadarsini C; Shankar S; Hanna LE; Murhekar M; Devi KRU; Babu S
    J Travel Med; 2022 Sep; 29(6):. PubMed ID: 35900009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
    Bhatnagar T; Chaudhuri S; Ponnaiah M; Yadav PD; Sabarinathan R; Sahay RR; Ahmed F; Aswathy S; Bhardwaj P; Bilimale A; Kumar MS; Logaraj M; Narlawar U; Palanivel C; Patel P; Rai SK; Saxena V; Singh A; Thangaraj JW; Agarwal A; Alvi Y; Amoghashree ; Ashok P; Babu D; Bahurupi Y; Bhalavi S; Behera P; Biswas PP; Charan J; Chauhan NK; Chetak KB; Dar L; Das A; Deepashree R; Dhar M; Dhodapkar R; Dipu TS; Dudeja M; Dudhmal M; Gadepalli R; Garg MK; Gayathri AV; Goel AD; Gowdappa HB; Guleria R; Gupta MK; Islam F; Jain M; Jain V; Jawahar MLS; Joshi R; Kant S; Kar SS; Kalita D; Khapre M; Khichar S; Kombade SP; Kohli S; Kumar A; Kumar A; Kumar D; Kulirankal KG; Leela KV; Majumdar T; Mishra B; Misra P; Misra S; Mohapatra PR; Murthy MN; Nyayanit DA; Patel M; Pathania M; Patil S; Patro BK; Jalandra R; Rathod P; Shah N; Shete A; Shukla D; Shwethashree M; Sinha S; Sumana MN; Surana A; Trikha A; Tejashree A; Venkateshan M; Vijaykrishnan G; Wadhava S; Wig N; Gupta N; Abraham P; Murhekar MV
    Int J Infect Dis; 2022 Sep; 122():693-702. PubMed ID: 35843496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin.
    Kant R; Dwivedi G; Zaman K; Sahay RR; Sapkal G; Kaushal H; Nyayanit DA; Yadav PD; Deshpande G; Singh R; Chaowdhary S; Gupta N; Kumar S; Abraham P; Panda S; Bhargava B
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34652440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Media Reporting Relating to COVID-19 Vaccination as a Driver of Vaccine Hesitancy Prior to the Second Wave of the COVID-19 Pandemic in India: A Content Analysis of Newspaper and Digital Media Reports.
    Basu S; Sharma H
    Cureus; 2023 Mar; 15(3):e36750. PubMed ID: 37123709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study.
    Kumar NP; Padmapriyadarsini C; Uma Devi KR; Banurekha VV; Nancy A; Girish Kumar CP; Murhekar MV; Gupta N; Panda S; Babu S; Bhargava B
    Indian J Med Res; 2021 May; 153(5&6):671-676. PubMed ID: 34528524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications, Efficacy, and Adverse Effects of Inactivated Whole-Virus COVID-19 Vaccines Sinopharm, CoronaVac, and Covaxin: An Observational Study.
    Meo SA; ElToukhy RA; Meo AS; Klonoff DC
    Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.